Search jobs First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Breakthrough results in the treatment of a type of heart failure, which is extremely difficult to manage
Strong progress in mental health pipeline
Good business performance in all areas, despite ongoing impact of COVID-19
Ingelheim, August 3, 2021 – In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The company’s success is based on its rich R&D portfolio with a focus on diseases with high unmet medical need. The R&D pipeline in Human Pharma comprises more than 60 new substances and around 100 clinical and pre-clinical projects. This pipeline has the potential to deliver up to 15 medicines for approval by 2025.
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim, Lifebit to use AI to detect infectious disease outbreaks
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim to detect animal diseases using AI
9 June 2021 |
The captured insights can accelerate detection of the latest animal disease outbreaks
Animal health firm Boehringer Ingelheim will partner with Lifebit Biotech to utilise artificial intelligence for the detection of global disease outbreaks.
Technology firm Lifebit’s REAL platform automatically detects and tracks animal disease outbreaks using real-world evidence and AI.
The captured insights can accelerate detection of the latest outbreaks including transboundary diseases and emerging pathogens.
Now researchers from the two organisations will work to combine real-world evidence and the latest AI algorithms to identify infectious disease outbreaks and respond accordingly.